Program
obexelimab
Also written as “Obexelimab” and “XmAb5871”.
Its studies are mostly in Lupus Erythematosus, Systemic · Immunoglobulin G4-Related Disease · Multiple Sclerosis · Anemia, Hemolytic, Autoimmune, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zenas BioPharma (USA) | 44 open or running | phase 3since Dec 14, 2022 | Dec 14, 2022 | none ahead |
| Xencor | 30 open or running | phase 2since Jan 8, 2016 | Jan 8, 2016 | none ahead |
- Named in bristol myers squibb’s own pipeline as
obexelimab
, phase 4, as of Oct 29, 2026 (source).
Also a collaborator on its studies: Bristol-Myers Squibb, ppd-development-lp, icon-plc and parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 8, 2016First study: phase 2 study in Lupus Erythematosus, SystemicNew to XencorXencor · NCT02725515 · 105 enrolled · United States
- Mar 4, 2016Phase 2 study in Immunoglobulin G4-Related DiseaseXencor · NCT02725476 · 20 enrolled · United States
- Aug 2, 2016Phase 1 study in Healthy VolunteersXencor · NCT02867098 · 50 enrolled · United States
- Dec 14, 2022Zenas BioPharma (USA)'s first study: phase 3 study in Immunoglobulin G4-Related DiseaseNew to Zenas BioPharma (USA)Zenas BioPharma (USA) · NCT05662241 · 194 enrolled · United States, Argentina, Canada and more
- Mar 13, 2023Phase 3 study in Warm Autoimmune Hemolytic AnemiaZenas BioPharma (USA) · NCT05786573 · 134 enrolled · Italy, Poland, Spain and more
- Aug 14, 20242 phase 2 studiesZenas BioPharma (USA) · NCT06559163, NCT06564311
TargetBeta
“A humanized immunoglobulin G1 (IgG1) noncytolytic monoclonal antibody directed against the B-cell-specific cell surface antigen CD-19, Fc-engineered for increased affinity to Fc gamma receptor IIB (FcgRIIB; CD32B), with potential immunomodulatory activity. Upon administration, obexelimab simultan…”NCIt, read by Claude
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06564311Multiple Sclerosis · United States, Austria, Belgium and more | 2 | Active, not recruiting | Zenas BioPharma (USA) | Aug 28, 2025 | 93 |
| NCT06559163Lupus Erythematosus, Systemic · United States, Belgium, Bulgaria and more | 2 | Active, not recruiting | Zenas BioPharma (USA) | Sep 2026 | 190 |
| NCT05786573Warm Autoimmune Hemolytic Anemia · Italy, Poland, Spain and more | 3 | Active, not recruiting | Zenas BioPharma (USA) | Jun 30, 2026 | 134 |
| NCT05662241Immunoglobulin G4-Related Disease · United States, Argentina, Canada and more | 3 | Active, not recruiting | Zenas BioPharma (USA) | Nov 13, 2025 | 194 |
| NCT02867098Healthy Volunteers · United States | 1 | Completed | Xencor | Oct 21, 2016 | 50 |
| NCT02725476Immunoglobulin G4-Related Disease · United States | 2 | Completed | Xencor | Dec 2017 | 20 |
| NCT02725515Lupus Erythematosus, Systemic · United States | 2 | Completed | Xencor | Jul 17, 2018 | 105 |
How it is read
Names in the registry
- “Obexelimab”, 5 entries
- “XmAb5871”, 3 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 2 studies
- Immunoglobulin G4-Related Disease, 2 studies
- Multiple Sclerosis, 1 study
- Anemia, Hemolytic, Autoimmune, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.